Cyclic peptides and peptoids were prepared using the thiol-ene Michael-type reaction.
INTRODUCTION
With respect to the linear counterparts, conformationally constrained peptides offer increased bioavailability and affinity for the target. 1 Cell uptake has been shown to increase if cyclization is accompanied by the formation of internal H-bonds, which reduces the cost of amide bond desolvation. 2, 3 Suitably derivatized cyclic peptides can be used as scaffolds (cyclic decapeptide RAFT 4 is an example) for the assembly of different moieties (epitopes, drugs, ligands, labels, etc.) at predetermined positions, affording biomolecules with a degree of structural organization much higher than the one accessible through derivatization of a linear peptide. Furthermore, cyclic peptides hold promise to interfere with protein-protein or protein-RNA interactions (references 5-7 are some examples of recent publications on these subjects).
A survey of the latest literature shows that the synthesis of conjugates of cyclic peptides is an active subject of research. In a large number of papers the affinity of α V β 3 integrin have been prepared to improve pharmacological properties [10] [11] [12] [13] [14] [15] and to investigate new materials. 16, 17 Amide-linked units form most of these peptides, while some incorporate unnatural linkages. As to the conjugation chemistry, formation of peptide bonds and the Michaeltype reaction between a maleimide and a thiol are the most common alternatives, but other "click" reactions, and particularly the Cu(I)-catalyzed azide-alkyne cycloaddition, are becoming increasingly frequent.
There are very few reports on the synthesis and application of [cyclic peptide]-oligonucleotide conjugates. Hamilton and coworkers 18 linked cyclic tetrapeptides to guanine-rich oligonucleotides that assembled onto a parallel tetraplex. The distribution of the peptide ligands on the vertexes of the top tetrad provided an α-chymotrypsin inhibitor that effectively interacted with the protein surface. In a related approach, the covalent attachment of peptides to the 5' ends of two guanine-rich oligonucleotides provided, in the presence of potassium cations, a parallel G-quadruplex with two loop mimics on its surface. 19 Cyclic peptides have been covalently linked to the sense strand of a siRNA duplex, which facilitated transport of the oligonucleotide through the cell membrane and inhibited gene expression. 20 More recently, disulfide-containing citrullinated peptides have been linked to various oligonucleotides and immobilized on plates for diagnostic ELISA assays. 21 In this manuscript we wish to describe methodology allowing for the straightforward synthesis of [cyclic peptide]-oligonucleotide conjugates. Model peptides (and a peptoid) cyclized using the Michael-type maleimide-thiol reaction 22 and incorporating a functional group allowing for subsequent conjugation were prepared. Then, oligonucleotides were linked to different positions (internal or external) of the cyclic polyamide using various click reactions, namely the Diels-Alder and Cu(I)-catalyzed Huisgen cycloadditions, or, again, the Michael-type thiol-ene. We believe that easy access to [cyclic peptide]-oligonucleotide conjugates will pave the way for new studies aiming at assessing whether cyclic peptides facilitate the cell uptake of oligonucleotides, and promote interactions with cell machineries different from those driven by the linear oligomers. To our knowledge, whether the gene silencing or spliceswitching properties of oligonucleotides linked to cyclic peptides differ from those of [linear peptide]-oligonucleotide conjugates has never been assessed.
RESULTS
As recently described by the group, 22 peptides can be cyclized by reaction between a maleimide and a thiol. Cyclic peptides can be obtained from linear precursors after the TFA treatment that deprotects the peptide chain following stepwise elongation on a solid matrix, using S-trityl protected cysteine and a maleimide moiety (Scheme 1A).
Since the maleimide moiety is labile to nucleophiles such as piperidine, which is used at every synthesis cycle to remove the Fmoc temporary protecting group, it can only be installed at the N-terminus. For introduction at any other position of the chain the maleimide has to be protected, for which purpose an Fmoc-lysine derivative with 2,5-dimethylfuran-protected 3-maleimido-propanoic acid linked to the ε-amine can be used. 23 In this case the cyclic peptide is not obtained after the reaction with TFA but after the thermal treatment that deprotects the maleimide.
Cyclic peptides can be derivatized for conjugation in three different ways (see Scheme 1B). In cyclic peptides types I and II, the functional group for conjugation (depicted as a triangle) is outside the cycle, and the cycle involves, respectively, amino acids placed at either the N-terminus of the peptide chain (the group for conjugation is then placed at the C-terminus) or the C-terminus (and the group for conjugation is at the N-terminus).
In type III cyclic peptides the group for conjugation is within the cycle.
Linear precursors incorporating a free and a protected maleimide are needed to synthesize maleimido-derivatized cyclic peptides. The free maleimide, which will form the cycle, can only be placed at the N-terminal end, while the protected moiety can occupy any other position. As stated above, if the protected maleimide is closer to the C-terminus than the thiol involved in cyclization, the result is a type I cyclic peptide (Scheme 1C, alternative a). These peptides can be conjugated with either thiol-or dienederivatized molecules. Peptides were prepared by solid-phase synthesis using the standard Fmoc/ t Bu methodology. All were assembled on the Rink amide MBHA (pmethylbenzhydrylamine) resin, and were thus obtained as C-terminal carboxamides.
Acylation with 3-maleimidopropanoic acid after chain elongation allowed a free maleimide to be attached to the peptide N-terminus.
These compounds were conjugated with suitably derivatized oligonucleotides (or nucleoside), as shown in Schemes 2-5 in more detail. Diene-and maleimido-containing oligonucleotides (dT 5 , dT = 2'-deoxythymidine) were synthesized following described procedures. 26, 27 Schemes 2, 3 and 4 illustrate in more detail the different steps required to obtain cyclic peptides types I to III, and the corresponding conjugation products.
Synthesis and conjugation of a type I cyclic peptide
In the first alternative (aimed to provide type I cyclic peptide, a in Scheme 1B), the fully protected peptide precursor (1) incorporated two maleimides, one free (at the Nterminus) and one protected (at the C-terminus), and a trityl-protected cysteine residue (Scheme 2). Therefore, the TFA treatment that was carried out after assembly of the linear precursor removed all protecting groups except that on the C-terminal maleimide, and, as previously described, 22 furnished the partially protected cyclic peptide 2.
Maleimide thermal deprotection (retro-Diels-Alder reaction) was performed subsequently in the presence of 5'-diene-dT 5 , which afforded the target conjugate 3.
Scheme 2. Synthesis of type I cyclic peptide 2 and conjugation with oligonucleotide dT 5 .
Abbreviations: Pbf = 2,2,4,6,7-pentamethyldihydro-benzofuran-5-sulfonyl.
Synthesis and conjugation of a type II cyclic peptide
The goal of the second alternative (b in Scheme 1B) was to obtain a peptide with a free thiol group for conjugation at the N-terminus of the chain (type II cyclic peptide). This required a precursor with two differently protected cysteines and a protected maleimide (Scheme 3). The cysteine that had to participate in cyclization was protected with the TFA-labile trityl group, and it was necessary to assess which thiol protecting group was suitable for the other cysteine. This group had to remain stable during the treatments required to obtain the cycle, that is, TFA treatment and maleimide deprotection. ). Yet, when peptide 5 was submitted to these reaction conditions, two products were obtained (Scheme 3a): the target compound (6) with the thiosuccinimide-containing cycle, and a peptide (7) with a disulfide bridge and a free maleimide (the 6:7 ratio was 1:1 when the peptide was heated for 30 min, and 3:2 when the reaction was extended to the 90 min typically required for full maleimide deprotection 27 ).
Mass spectrometric analysis confirmed presence of the S t Bu group in 6, its loss after reaction with tris(2-carboxyethyl)phosphine (TCEP) to yield 16 (see structure in Scheme 3c), and loss of the three N-terminal amino acids when 6 was digested with thrombin. Instead, the mass of 7 was lower than that of 6, and the product remained 
Synthesis and conjugation of type III cyclic polyamides (peptide and peptoid)
Two different type III cyclic polyamides were synthesized (alternatives c and d in Scheme 1B). Here the functional group for conjugation appended from a residue placed within the cycle. In one case the polyamide was a peptide and the functional group for conjugation a thiol (20) , while in the other it was a peptoid derivatized with an alkyne (24) .
Scheme 4 depicts the preparation and conjugation of cyclic peptide 20. The C-terminal cysteine was protected with the trityl group, which reacted with the N-terminal, free maleimide upon treatment with TFA. Under these conditions the free thiol gave the Michael-type reaction and left untouched the internal, S t Bu-protected cysteine residue.
In other words, the free thiol reacted much faster with the maleimide than with the S t Bu-protected cysteine. The side chain of the internal cysteine of the cyclic peptide (19) was deprotected by reaction with TCEP and, after purification, reacted with 5'-maleimido-dT 5 to yield conjugate 21.
Scheme 4.
Steps involved in the preparation of cyclic peptide 20 and conjugate 21.
Scheme 5 shows the preparation of a cyclic peptoid and the structure of the derived conjugate. On-resin assembly of the peptoid was carried out using the submonomer procedure, 29 also on the Rink amide MBHA resin. As shown in the upper part of the scheme, chain elongation involves two subsequent steps, namely acylation with bromoacetic acid and reaction with an amine. Three of the amines required to synthesize peptoid 23 were commercially available (see list at the Supporting Information), and S-Tr-protected cysteamine and N-Boc-1,2-diaminoethane were prepared following described procedures. 30, 31 Cyclization with an N-terminal maleimide required incorporation of a maleimide-containing monomer, and 3-maleimidopropanoic acid is the cheapest alternative. However, since we had observed that the quality of cyclic peptide crudes was a bit lower when cyclization took place upon treatment with TFA, 22 we incorporated the 2,5-dimethylfuran-protected maleimidopropanoic acid. 27 To introduce maleimide moieties at other positions of the chain, 2-[(2,5-dimethylfuranprotected) maleimide]-1-aminoethane 23 should be employed. In the absence of two orthogonal maleimide protecting groups, this precludes use of maleimides for subsequent conjugation. Chain assembly furnished the fully protected peptoid 22, from which all protecting groups except that on the maleimide were removed by treatment with TFA. Maleimide deprotection and cyclization took place simultaneously to afford 24. Finally, the Cu(I)-catalyzed Huisgen reaction between cyclic peptoid 24 and AZT (2',3'-dideoxy-3'-azidothymidine) provided the target conjugate (25) . The azide-containing molecule was in this case a simple nucleoside analog, but the high success of the Cu(I)-catalyzed alkyne-azide cycloaddition has prompted many groups to develop methodology for the preparation of azide-derivatized oligonucleotides (see, for instance, references [32] [33] [34] circumventing the incompatibility between azides and phosphite-based reagents.
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DISCUSSION
We have shown that, by adequately combining differently protected cysteines, free and protected maleimides, and an alkyne, and choosing their relative position in the chain, it is possible to easily obtain cyclic peptides derivatized with a functional group allowing for subsequent conjugation, for instance with oligonucleotides.
In all cases cyclization was carried out using the thiol-ene Michael-type reaction. For this purpose, in all peptide precursors one of the cysteine residues was masked with the TFA-labile trityl group, so that the acidic treatment that follows chain elongation deprotected its thiol. When a free maleimide had been appended to the N-terminus of the chain, this unmasked thiol reacted with the maleimide to form the cycle (peptides 2 and 19) during the TFA deprotection step. 22 Whenever a masked maleimide was incorporated into the chain, an additional deprotection step was required. Then, thermal removal of the maleimide protecting group (retro-Diels-Alder reaction) and cyclization took place simultaneously (peptide 14 and peptoid 24).
As required for conjugation with a suitably derivatized molecule, cyclic peptides had to incorporate an additional functional group. In this work, this group was either a maleimide, a thiol, or an alkyne.
With the cyclization strategy that we have used, the only possibility to use a maleimide for conjugation is to assemble a peptide precursor with a free maleimide at the N- When the cyclic peptide is to be derivatized with a thiol for conjugation, the choice of protecting group for the cysteine providing this thiol depends on its position in the chain. If the goal is a type II cyclic peptide, the best alternative among those we have examined is to block the thiol with the Fm group, which is compatible with maleimide deprotection and cyclization and can be removed with no formation of byproducts. The only drawback is that removal of the Fm group by reaction with piperidine is accompanied by disulfide formation, an additional reduction step being thus necessary prior to conjugation. N-Terminal derivatization of a peptide with a thiol was here accomplished by introducing either suitably protected cysteine residue, but an S-blocked mercaptoacetic acid should also work. Use of cysteine derivatives has the advantage that the amino function can be further derivatized, allowing for the attachment a fluorophore, for instance, or any reporter group.
Conversely, the synthesis of cyclic peptides with the cysteine that provides the thiol for conjugation at any other position of the chain (not at the N-terminus) is much more straightforward (this is the case of type III peptide 20, but the same protection scheme could provide type I peptides). That cysteine can indeed be protected with the S t Bu group, which remains stable during the acidic treatment that removes most of the protecting groups from the peptide and does not react with the free thiol resulting from the deprotection of Cys(Tr) (or if it does, the extent of the reaction is negligible). As stated before, at room temperature and under these strongly acidic conditions, formation of the cycle by reaction between the free thiol and the free maleimide is much quicker.
Yet (see above and Scheme 3a), this is not the case when the peptide has to be heated.
Thiol-derivatized cyclic peptides can be conjugated with maleimido-oligonucleotides, as in the case of 17 and 21.
Type III cyclic peptoids derivatized for conjugation by the Cu(I)-catalyzed Huisgen cycloaddition were also synthesized. In this case the key monomers were 3-(2,5-dimethylfuran-protected)maleimidopropanoic acid, 27 S-trityl-cysteamine 30 and propargylamine. Use of S-Fm-cysteamine instead of propargylamine would provide peptoids cyclized by the thiol-maleimide reaction and derivatized with a thiol group for conjugation.
As to the use of alkynes for conjugation, the triple bond can be installed at any position of the polyamide chain. It is neither affected by any of the peptide/peptoid synthesis reagents, nor by the thiol-maleimide cycle-forming reaction. We have prepared a [cyclic peptoid]-nucleoside conjugate to verify that synthesis proceeded as expected, and the triple bond was introduced in an internal position by reacting propargylamine with the haloacylated resin-linked, growing peptoid chain. Commercially available alkynecontaining L-amino acids or alkynoic acids allow triple bonds to be attached to peptides in a straightforward manner, which is also the case for derivatization with azides.
CONCLUSIONS
In summary, we have broadened the scope of applications of peptides cyclized making use of the maleimide-thiol reaction by introducing an additional group that allows for conjugation with oligonucleotides (or other molecules) utilizing click reactions, and
shown that this methodology can also be employed with peptoids. The method here described is based on the adequate choice of protection for maleimides and thiols, as well as suitably placing maleimides, thiols or alkynes within the peptide/peptoid chain.
These synthetic alternatives could also provide other cyclic polyamide scaffolds derivatized for conjugation, such as peptide nucleic acids.
It has been reported that subtle differences in the conjugation chemistry may have considerable impact on the biological outcome. [37] [38] [39] Therefore, it is of interest to develop chemical tools giving access to differently linked conjugates. This manuscript describes methodology allowing oligonucleotides to be linked to cyclic peptides, either to an internal position, or to any of the two ends of a chain in which only some of the residues of the peptide are part of a chemically stable cycle. Both cyclic peptides and oligonucleotides (natural or modified) are relevant chemical goals that hold promise from the therapeutic and diagnostics point of view. So far there is lack of information as to the differential effect of linking oligonucleotides to cyclic peptides rather than the linear counterparts. Work on this subject is now in progress in the group, and results will be published in due time. Alternatively, methanol removal was followed by lyophilization, and the crude was redissolved in water for HPLC analysis.
Assessment of cyclization: Reaction with H 2 O 2 . Formation of a cyclic product was
confirmed by reacting the peptide, either linear or cyclic, with a dilute solution of H 2 O 2 (3.5%) for 1 h, and subsequent MS analysis. 23 When the peptide is linear, H 2 O 2 oxidizes the free thiol to sulfonic acid (and the mass increases 48 units), whereas when the peptide is cyclic the thioether is oxidized to sulfoxide (and the mass increases 16 units).
This method cannot be used when the peptide to be analyzed incorporates a Cys(S t Bu) residue, because this disulfide is oxidized to different products. ESI Mass spectrometric analysis showed formation of mixtures of products with and without loss of the S t Bu group. When analysis was performed in the negative mode, the main group of peaks corresponded to loss of the S t Bu group and oxidation of the thiol to sulfonic acid (+ 3 oxygen atoms, M+48). Reaction with Tl(OAc) 3 . Compound 11 (50 nmol) was dissolved in TFA (500 µL), and a solution of Tl(OAc) 3 (390 µg, 100 nmol) and anisole (10.9 µL, 100 nmol) in TFA (10 µL) was added. The mixture was reacted for 1 h at 0 ºC, and the solvent was removed with a N 2 stream. 10% Acetic acid in water (1 mL) and chloroform (1 mL) were added, and the two fractions were collected separately. HPLC and MALDI-TOF analysis of the two fractions showed the presence of multiple products, none of which could be identified. 
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